{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:06:41Z","timestamp":1773526001846,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The recent introduction of ABP 501, an adalimumab biosimilar, in the treatment of rheumatic diseases was supported by a comprehensive comparability exercise with its originator. On the other hand, observational studies comparing adalimumab and ABP 501 in inflammatory arthritis are still lacking. The main aim of this study is to compare the clinical outcomes of the treatment with adalimumab, both the originator and ABP 501, in a large cohort of patients affected by autoimmune arthritis in a real life setting. We retrospectively analysed the baseline characteristics and the retention rate in a cohort of patients who received at least a course of adalimumab (originator or ABP 501) from January 2003 to December 2020. We stratified the study population according to adalimumab use: naive to original (oADA), naive to ABP 501 (bADA) and switched from original to ABP 501 (sADA). The oADA, bADA and sADA groups included, respectively, 724, 129 and 193 patients. In each group, the majority of patients had a diagnosis of rheumatoid arthritis. The total observation period was 9805.6 patient-months. The 18-month retentions rate in oADA, bADA and sADA was, respectively, 81.5%, 84.0% and 88.0% (p &gt; 0.05). The factors influencing the adalimumab retention rate were an axial spondylarthritis diagnosis (Hazard Ratio (HR) 0.70; p = 0.04), switch from oADA to ABP 501 (HR 0.53; p = 0.02) and year of prescription (HR 1.04; p = 0.04). In this retrospective study, patients naive to the adalimumab originator and its biosimilar ABP 501 showed the same retention rate. Patients switching from the originator to biosimilar had a higher retention rate, even though not statistically significant, when compared to naive.<\/jats:p>","DOI":"10.3390\/jpm12030335","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T22:54:02Z","timestamp":1645656842000},"page":"335","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-8511","authenticated-orcid":false,"given":"Andrea","family":"Becciolini","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medicine and Internal Medicine, University Hospital of Parma, 43121 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-8315","authenticated-orcid":false,"given":"Simone","family":"Parisi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of General and Specialistic Medicine, Azienda Ospedaliero-Universitaria, Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalba","family":"Caccavale","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bravi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ospedale Guglielmo da Saliceto, 29121 Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Lumetti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda USL of Modena and AOU Policlinico of Modena, 41100 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Andracco","sequence":"additional","affiliation":[{"name":"Distretto Socio Sanitario ASL 1 Imperiese, 18001 Imperia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Volpe","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, IRCCS Sacro Cuore Don Calabria, 37024 Negrar, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Gardelli","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, GB Morgagni Hospital, 47121 Forli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6075-9989","authenticated-orcid":false,"given":"Francesco","family":"Girelli","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, GB Morgagni Hospital, 47121 Forli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Di Donato","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine and Internal Medicine, University Hospital of Parma, 43121 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-7821","authenticated-orcid":false,"given":"Daniele","family":"Santilli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine and Internal Medicine, University Hospital of Parma, 43121 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Lucchini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine and Internal Medicine, University Hospital of Parma, 43121 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5025-287X","authenticated-orcid":false,"given":"Maria Chiara","family":"Ditto","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of General and Specialistic Medicine, Azienda Ospedaliero-Universitaria, Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Plat\u00e8","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ospedale Guglielmo da Saliceto, 29121 Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Arrigoni","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ospedale Guglielmo da Saliceto, 29121 Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Mozzani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine and Internal Medicine, University Hospital of Parma, 43121 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Riva","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine and Internal Medicine, University Hospital of Parma, 43121 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Marchetta","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, IRCCS Sacro Cuore Don Calabria, 37024 Negrar, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9888-2563","authenticated-orcid":false,"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of General and Specialistic Medicine, Azienda Ospedaliero-Universitaria, Citt\u00e0 della Salute e della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0454-1093","authenticated-orcid":false,"given":"Gilda","family":"Sandri","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Modena and Reggio Emilia, 41100 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Modena and Reggio Emilia, 41100 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-9128","authenticated-orcid":false,"given":"Marino","family":"Paroli","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-6102","authenticated-orcid":false,"given":"Alarico","family":"Ariani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine and Internal Medicine, University Hospital of Parma, 43121 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","article-title":"The role of biosimilars in the treatment of rheumatic diseases","volume":"72","author":"Strand","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2174\/1389201019666171226151852","article-title":"Biologics in inflammatory and immunomediated arthritis","volume":"18","author":"Luchetti","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40259-016-0185-2","article-title":"Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab","volume":"30","author":"Velayudhan","year":"2016","journal-title":"BioDrugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40259-016-0184-3","article-title":"Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab","volume":"30","author":"Liu","year":"2016","journal-title":"BioDrugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2015-208914","article-title":"A Randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab","volume":"76","author":"Kaur","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","article-title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13075-019-1857-3","article-title":"An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis","volume":"21","author":"Cohen","year":"2019","journal-title":"Arthritis. Res. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.2004.028530","article-title":"Why results of clinical trials and observational studies of antitumour necrosis factor (Anti-TNF) therapy differ: Methodological and interpretive issues","volume":"63","author":"Wolfe","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ribaldone, D.G., Tribocco, E., Rosso, C., Armandi, A., Vernero, M., Bugianesi, E., Astegiano, M., Saracco, G.M., and Caviglia, G.P. (2021). Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn\u2019s disease: A prospective study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153387"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1111\/jgh.15590","article-title":"SPOSAB ABP 501: A sicilian prospective observational study of patients with inflammatory Bowel disease treated with adalimumab biosimilar ABP 501","volume":"36","author":"Macaluso","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/03007995.2021.1923467","article-title":"A Single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the Treatment of plaque-type psoriasis and psoriatic arthritis in originator-na\u00efve patients and in patients undergoing non-medical switch from originator","volume":"37","author":"Giunta","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10368","DOI":"10.1038\/s41598-021-89790-4","article-title":"Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator","volume":"11","author":"Cingolani","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.17235\/reed.2020.6693\/2019","article-title":"Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn\u2019s disease: An observational study","volume":"112","author":"Ribaldone","year":"2020","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3389\/fphar.2019.01497","article-title":"Effectiveness of adalimumab for the treatment of psoriatic arthritis: An italian real-life retrospective study","volume":"10","author":"Cantini","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/acr.23090","article-title":"Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: A multicenter retrospective analysis: Survival of TNF inhibitors over eight years in SpA","volume":"69","author":"Favalli","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: Real-life data from a local registry: Long-term persistence on infliximab, etanercept, and adalimumab","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_17","first-page":"1400","article-title":"Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: Nationwide observational study emulating a randomised clinical trial","volume":"80","author":"Nabi","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2147\/DDDT.S162286","article-title":"The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: Retrospective analysis of a local registry","volume":"12","author":"Favalli","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13075-020-02337-2","article-title":"Differences between men and women with nonradiographic axial spondyloarthritis: Clinical characteristics and treatment effectiveness in a real-life prospective cohort","volume":"22","author":"Neuenschwander","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lee, J.-W., Kang, J.-H., Yim, Y.-R., Kim, J.-E., Wen, L., Lee, K.-E., Park, D.-J., Kim, T.-J., Park, Y.-W., and Lee, S.-S. (2015). Predictors of switching anti-tumor necrosis factor therapy in patients with ankylosing spondylitis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131864"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"ARTIS study group drug survival on tnf inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","first-page":"857","article-title":"Drug survival of the first course of Anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: Analysis from the MonitorNet Database","volume":"31","author":"Caporali","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti\u2013tumor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10067-020-05199-w","article-title":"Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases","volume":"40","author":"Bruni","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16178","DOI":"10.1038\/s41598-020-73183-0","article-title":"Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis","volume":"10","author":"Ditto","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_27","first-page":"29","article-title":"Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product","volume":"9","author":"Abdalla","year":"2017","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e001016","DOI":"10.1136\/rmdopen-2019-001016","article-title":"Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A danish register-based study of patients with inflammatory arthritis","volume":"5","author":"Glintborg","year":"2019","journal-title":"RMD Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 Patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","article-title":"To switch or not to switch: Results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry","volume":"78","author":"Glintborg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5152\/eurjrheum.2020.20080","article-title":"bDMARDs Retention Rate in the Biosimilar Era: A Real-Life Monocentric Study","volume":"8","author":"Becciolini","year":"2021","journal-title":"Eur. J. Rheumatol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/3\/335\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:26:10Z","timestamp":1760135170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/3\/335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jpm12030335"],"URL":"https:\/\/doi.org\/10.3390\/jpm12030335","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]}}}